Trials / Completed
CompletedNCT02537834
Tofogliflozin GLP-1 Analogue Combination Trial
An Open-Label, Multicenter Study to Evaluate 52-Week Long-Term Safety, Tolerability and Efficacy of Tofogliflozin With Glucagon-like Peptide-1(GLP-1) Analogue Treatment In Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 65 (actual)
- Sponsor
- Kowa Company, Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
An open-label, multicenter study to evaluate 52-week long-term safety, tolerability and efficacy of Tofogliflozin with GLP-1 analogue treatment in type 2 diabetes mellitus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tofogliflozin | |
| DRUG | GLP-1 analogue |
Timeline
- Start date
- 2015-08-01
- Primary completion
- 2017-07-01
- Completion
- 2017-10-01
- First posted
- 2015-09-02
- Last updated
- 2020-11-17
Locations
11 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02537834. Inclusion in this directory is not an endorsement.